Sandoz Ag

Basf Se Corporation

Lek Pharmaceuticals D.d.

Mipa Se

Ulrich Griesser

Christoph Langes

Andreas Hotter

Josef Wieser

Arthur Pichler

Marijan Stefinovic

Johannes Ludescher

Hubert Sturm

Michael Enders

Markus Gewehr

Peter Erk

Heidi Emilia Saxell

Eike Hupe

Hannes Lengauer

Erwin Schreiner

Verena Adamer

Lovro Selic

Herwig Schottenberger

Nolwenn Martin

Robert Ziegert-Knepper

Thomas Gelbrich

Clemens Haefele

Dennis Dimo Enkelmann

Richard Tessadri

Doris Braun

Michaela Tischler

Christian Laschober

Mairi Haddow

Volker Kahlenberg

Robert Salchner

Roman Lackner

Robert E Ziegert-Knepper

The present invention relates to co-crystals comprising levothyroxine and a dicarboxylic acid, preferably L-tartaric acid or oxalic acid, and processes for the preparation thereof. Furthermore, the invention relates to a pharmaceutical composition comprising a co-crystal of the present invention, preferably the co-crystal comprising levothyroxine and L-tartaric acid or oxalic acid, and at least one pharmaceutically acceptable excipient. The pharmaceutical composition of the present invention can be used as a medicament, in particular for the treatment of hypothyroidism.

Co-crystals comprising levothyroxine and a dicarboxylic acid

The present invention relates to crystalline valbenazine ditosylate, in particular to a crystalline hydrate of valbenazine ditosylate and a crystalline anhydrate of valbenazine ditosylate, and to methods for their preparation. Furthermore, the invention relates to a pharmaceutical composition comprising the crystalline hydrate or the crystalline anhydrate, preferably in an effective and/or predetermined amount and to the use of said pharmaceutical composition as a medicament, in particular for the treatment of hyperkinetic movement disorders such as tardive dyskinesia. 

Crystalline forms of valbenazine salts

The present invention relates to non-stoichiometric crystalline hydrates of 1-(&#x3b2;-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene, processes for their preparation, and their use as medicaments. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel crystalline hydrates.

Crystalline hydrates of 1-(&#x3b2;-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene

The present invention relates to novel crystalline forms of ceftaroline fosamil and to methods for their preparation. Furthermore the present invention relates to the use of the novel forms of ceftaroline fosamil for the preparation of an antibiotic medicament. In addition the present invention relates to pharmaceutical compositions comprising an effective amount of the novel forms of ceftaroline fosamil and to methods of preparing the same. Finally the present invention relates to pharmaceutical combinations comprising an effective amount of the novel forms of ceftaroline fosamil and &#x3b2;-lactamase inhibitors.

Crystalline forms of ceftaroline fosamil

The present invention is directed to a crystalline compound comprising a hydrobromide acid (HBr) salt of a compound of formula (I) (1-{2-[(2,4-dimethylphenyl)sulfanyl]phenyl}piperazine, INN: vortioxetine), having an XRPD pattern with characteristic peaks (expressed in 2&#x3b8;&#xb1;0.2&#xb0; 2&#x3b8; (CuK&#x3b1; radiation)) at 5.5&#xb0;, 14.8&#xb0;, 16.7&#xb0; and 20.0&#xb0; and processes for obtaining the same. 

Crystalline form of vortioxetine hydrobromide

The present invention relates to a novel solvate of ivabradine hydrochloride, a process of its preparation and its use for the preparation of specific polymorphic forms of ivabradine hydrochloride.

Acetone solvate of ivabradine hydrochloride

Provided are a crystalline dihydrate of Rivaroxaban, processes for the preparation thereof, pharmaceutical compositions containing the crystalline dihydrate and processes for preparing and storing the pharmaceutical compositions. Also provided are a crystalline formic acid solvate of Rivaroxaban, processes for the preparation of crystalline Rivaroxaban formic acid solvate and the use of the Rivaroxaban formic acid solvate in the manufacture of the crystalline dihydrate of Rivaroxaban.

Crystalline form of rivaroxaban dihydrate

The invention relates to a new solvate, Vilazodone hydrochloride monoethanol monohydrate solvate, and to a process for the preparation of polymorphic form III of Vilazodone hydrochloride via the Vilazodone hydrochloride monoethanol monohydrate solvate.

Process for the preparation of form III of vilazodone hydrochloride

The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions comprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.

Polymorphs of an active pharmaceutical ingredient

The present invention relates to a pharmaceutical composition comprising crystalline form Y of posaconazole. The pharmaceutical composition can be used to treat or prevent fungal infections.

Pharmaceutical compositions containing a crystalline form of posaconazole

The present invention relates to crystalline form IV of posaconazole and pharmaceutical compositions comprising the same. The pharmaceutical composition can be used to treat or prevent fungal infections.

Crystalline form of posaconazole

The present invention relates to two crystalline forms of 2-[2-chloro-4-methylsulfonyl-3-(2,2,2-trifluoro-ethoxymethyl)benzoyl]cyclohexan-1,3-dione, which is also known under the common name tembotrione. The invention also relates to a process for the production of these crystalline forms and formulations for plant protection which contain one of these crystalline forms of tembotrione.

Crystalline forms of 2-[2-chloro-4-methylsulfony1-3-(2,2,2-trifluoroethoxymethyl)benzoyl]cyclohexan-1,3-dione

The present invention relates to stable amorphous 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-&#x3b1;-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycin (telithromycin), methods for the preparation thereof, the use of stable amorphous telithromycin in the treatment of bacterial infections and to pharmaceutical compositions comprising stable amorphous telithromycin.

Amorphous telithromycin compound

The present invention relates to novel polymorphic forms of aripiprazole and processes for producing them. It further relates to pharmaceutical compositions comprising the novel forms and to the use of the novel forms in the treatment of schizophrenia.

Growing community of inventors

Innsbruck, Austria

Ulrich Griesser